Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Methods of Nuclear Reprogramming

Methods of Nuclear Reprogramming

Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for injury repair.

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A precision gene-engineered B cell medicine producing sustained levels of active factor IX for hemophilia B therapy.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Same author

Dopaminergic Therapies May Decrease Risk of Early and Intermediate Non-exudative Age-related Macular Degeneration Progression.

Ophthalmic surgery, lasers & imaging retina·2025

Same author

In vivo tracking of ex-vivo-generated <sup>89</sup>Zr-oxine-labeled plasma cells by PET in a non-human primate model.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Same author

Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing.

Molecular therapy : the journal of the American Society of Gene Therapy·2024

Same author

<i>In vivo</i> tracking of <i>ex vivo</i> generated <sup>89</sup> Zr-oxine labeled plasma cells by PET in a non-human primate model.

bioRxiv : the preprint server for biology·2024

Same author

Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes.

Frontiers in immunology·2023

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

Adoptive cell therapy: genetic modification to redirect effector cell specificity.

Richard A Morgan¹, Mark E Dudley, Steven A Rosenberg

¹Surgery Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA. rmorgan@mail.nih.gov

Cancer Journal (Sudbury, Mass.)

|August 10, 2010

Summary

This summary is machine-generated.

Genetically engineered T cells, using T-cell receptors or chimeric antigen receptors, show promise in treating cancer. These modified immune cells have demonstrated the ability to regress established tumors in human clinical trials.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jun 10, 2026

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Area of Science:

Immunology
Oncology
Genetic Engineering

Background:

Adoptive T-cell transfer is a recognized strategy for tumor regression.
Significant advancements in human gene transfer have enabled clinical applications.

Purpose of the Study:

To introduce two primary methods for redirecting effector T-cell specificity.
To review the genetic engineering of T cells for cancer therapy.

Main Methods:

Engineering primary human T cells to express exogenous T-cell receptors (TCRs).
Engineering primary human T cells to express chimeric antigen receptors (CARs).
Targeting multiple human tumor antigens with engineered T cells.

Main Results:

Demonstrated feasibility of administering engineered T cells to cancer patients.
Observed tumor regression mediated by both TCR- and CAR-engineered T cells in clinical trials.

Conclusions:

T-cell receptor and chimeric antigen receptor engineering represent viable approaches for cancer immunotherapy.
Engineered T cells hold significant potential for treating established human tumors.